all report title image
  • Published On : Jul 2023
  • Code : CMI6024
  • Pages : 160
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

The global Phenobarbital market size was valued at US$ 1.58 billion in 2023 and is expected to reach US$ 2.23 billion by 2030, grow at a compound annual growth rate (CAGR) of 5% from 2023 to 2030.

The Phenobarbital market is driven by its widespread use as an anticonvulsant medication for the treatment of various seizure disorders. Phenobarbital has a long history of use and is considered a first-line treatment for epilepsy, particularly in developing countries where it remains an affordable and accessible option. The market is fueled by the increasing prevalence of epilepsy and other seizure disorders, as well as the growing demand for effective anticonvulsant medications.

Phenobarbital Market Regional Insights

  • North America: North America is the largest market for Phenobarbital, accounting for a share of over 35% in 2022. In North America, including the United States and Canada, the Phenobarbital market is influenced by a well-developed healthcare system and a higher prevalence of alternative anticonvulsant medications. Phenobarbital may be less commonly prescribed compared to newer antiepileptic drugs, but it still has a role in certain cases, particularly in resource-limited settings.
  • Europe: Europe is the second-largest market for Phenobarbital, accounting for a share of over 25% in 2022. In Europe, the Phenobarbital market is influenced by variations in healthcare systems and regulations across different countries. Some European countries may have more restricted use of Phenobarbital, while others may still consider it as a viable treatment option for certain patients with epilepsy.
  • Asia Pacific: Asia Pacific is the fastest-growing market for Phenobarbital, accounting for a share of over 20% in 2022. Asia Pacific region, including countries like India and China, has a higher prevalence of epilepsy and limited access to newer antiepileptic drugs due to cost and availability. Phenobarbital remains an important and commonly prescribed anticonvulsant in this region due to its affordability and established efficacy.

Figure 1. Global Phenobarbital Market Share (%), by Region, 2023

 | Coherent Market Insights

Phenobarbital Market Drivers:

  • Established Efficacy: Phenobarbital has a long history of use and is known for its efficacy in the treatment of epilepsy and seizure It is considered a first-line treatment for certain types of seizures, particularly in resource-limited settings. The drug's effectiveness in controlling seizures contributes to its demand and utilization in the market.
  • Established Infrastructure: The availability of Phenobarbital is supported by an established infrastructure for manufacturing, distribution, and prescription. This infrastructure ensures the consistent supply of the medication to healthcare facilities and pharmacies, making it readily accessible for patients who require anticonvulsant therapy.
  • Prevalence of Epilepsy: The prevalence of epilepsy and seizure disorders is a significant driver of the Phenobarbital market. Epilepsy affects millions of people worldwide, and there is a constant demand for effective anticonvulsant medications. Phenobarbital, with its established efficacy, plays a crucial role in the management of epilepsy, especially in regions with a high prevalence of the condition.
  • Limited Access to Alternatives: In certain regions or healthcare settings, access to newer antiepileptic drugs may be limited due to factors such as cost, availability, or healthcare infrastructure. Phenobarbital, as a well-established and accessible treatment option, fills the gap in these situations and remains a valuable choice for managing seizures.

Phenobarbital Market Opportunities:

  • Expansion in Emerging Markets: There is an opportunity to expand the market for Phenobarbital in emerging economies, particularly in regions with a high burden of epilepsy and limited access to newer antiepileptic drugs. By targeting these markets and addressing the specific needs and challenges, pharmaceutical companies can tap into new customer bases and increase the availability of Phenobarbital as an affordable and effective treatment option.
  • Pediatric Formulations: Developing pediatric formulations of Phenobarbital presents an opportunity to cater to the specific needs of children with epilepsy. Pediatric dosing and formulations that are palatable and easy to administer can improve treatment adherence and outcomes. Considering the prevalence of epilepsy in children, this market segment holds significant potential for growth and provides an opportunity for companies to develop age-appropriate formulations.
  • Awareness and Education Initiatives: Increasing awareness and education about epilepsy and the role of Phenobarbital can create opportunities for market growth. Educational campaigns targeted at healthcare professionals, patients, and caregivers can help overcome stigma, improve understanding of epilepsy, and promote the appropriate use of Phenobarbital as a valuable treatment option. Such initiatives can drive demand and increase access to Phenobarbital in underserved communities.
  • Research and Development: Continued research and development efforts focused on optimizing the formulation, safety, and efficacy of Phenobarbital can unlock new opportunities in the market. This includes exploring novel delivery systems, extended-release formulations, and combination therapies that enhance the drug's therapeutic profile. Innovations in Phenobarbital formulation and development can contribute to improved patient outcomes and provide a competitive edge in the market.

Phenobarbital Market Trends:

  • Increasing Use of Generic Phenobarbital: The market has witnessed a growing trend towards the use of generic Phenobarbital formulations. Generic versions offer cost savings compared to branded counterparts, making them more accessible and affordable for patients and healthcare systems. The adoption of generic Phenobarbital is driven by factors such as cost containment efforts, expiration of patents for branded formulations, and the availability of high-quality generic options.
  • Shift Towards Individualized Treatment Approaches: There is a trend towards personalized and individualized treatment approaches in the management of epilepsy and seizure disorders, including the use of Phenobarbital. Healthcare providers are increasingly tailoring treatment regimens based on factors such as patient age, seizure type, comorbidities, and response to therapy. This approach allows for optimized treatment outcomes and minimization of side effects, driving the demand for Phenobarbital as part of personalized treatment strategies.
  • Integration of Technology: The integration of technology, such as electronic health records (EHRs), telemedicine, and mobile applications, is influencing the Phenobarbital market. These technological advancements facilitate remote monitoring, real-time data collection, and improved communication between healthcare providers and patients. Technology-enabled solutions can enhance treatment adherence, facilitate dose adjustments, and improve overall patient management, leading to better outcomes in Phenobarbital therapy.
  • Growing Emphasis on Safety and Side Effect Profile: With the increasing focus on patient safety, there is a trend towards monitoring and managing the side effects associated with Phenobarbital. Healthcare providers are actively assessing the potential risks and benefits of the medication and implementing strategies to mitigate adverse effects. This includes regular monitoring of blood levels, liver function, and cognitive function, as well as providing patient education on potential side effects and the importance of adherence to therapy.

Phenobarbital Market Report Coverage

Report Coverage Details
Base Year: 2022 Market Size in 2023: US$ 1.58 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 5% 2030 Value Projection: US$ 2.23 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East & Africa:  GCC Countries, Israel,  South Africa, North Africa, and Central Africa and Rest of Middle East
Segments covered:
  • By Indication: Epilepsy, Neonatal Seizures
  • By Dosage Form: Tablets, Injectable Formulations
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Sanofi, Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals, Zydus Cadila, Lannett Company,  Inc., Strides Pharma Science Limited, Cipla Ltd., Lupin Limited, Aurobindo Pharma Limited, Torrent Pharmaceuticals Ltd., Reddy's Laboratories Ltd.

Growth Drivers:
  • Established Efficacy
  • Established Infrastructure
  • Prevalence of Epilepsy
  • Limited Access to Alternatives
Restraints & Challenges:
  • Availability of Alternative Antiepileptic Drugs
  • Potential for Tolerance and Dependence
  • Adverse Effects and Safety Concerns

Phenobarbital Market Restraints:

  • Availability of Alternative Antiepileptic Drugs: The availability of alternative antiepileptic drugs with improved safety profiles and fewer side effects poses a restraint to the Phenobarbital market. Newer medications with different mechanisms of action and targeted indications have been developed, offering more options for managing epilepsy and seizure disorders. Healthcare providers may prefer to prescribe these newer drugs over Phenobarbital, especially in cases where minimizing side effects or drug interactions is a priority.
  • Potential for Tolerance and Dependence: Phenobarbital belongs to the barbiturate class of drugs, which have a potential for tolerance and dependence with prolonged use. This poses a challenge in long-term therapy, as the effectiveness of Phenobarbital may diminish over time, necessitating higher doses or alternative treatment strategies. The risk of dependence can also limit the use of Phenobarbital in certain patient populations, such as those with a history of substance abuse or addiction.
  • Adverse Effects and Safety Concerns: Phenobarbital is associated with various side effects, including sedation, cognitive impairment, dizziness, and behavioral changes. These adverse effects may impact patient compliance and quality of life, particularly in situations where the medication interferes with daily activities or cognitive function. Safety concerns related to the potential for serious hypersensitivity reactions or rare but severe adverse events also need to be considered, which may lead to cautious prescribing or monitoring practices.

Recent Developments

New product launches

  • In 2023, Spectrum Chemical Mfg. Corp. launched a new, high-purity phenobarbital product for use in research and clinical applications. The product is available in both powder and tablet form, and it is certified to meet USP standards.
  • In 2023, Mallinckrodt, Inc. launched a new generic version of phenobarbital tablets. The product is available in 15 mg, 30 mg, and 60 mg strengths, and it is covered by most major insurance plans.
  • In 2023, Sine Pharma launched a new, extended-release phenobarbital product. The product is designed to provide a more consistent level of medication throughout the day, and it is available in 100 mg and 150 mg strengths.

Acquisition and partnerships

  • In 2022, Spectrum Chemical Mfg. Corp. acquired the assets of Sine Pharma, a company that specialized in the development and commercialization of phenobarbital products. This acquisition gave Spectrum Chemical a strong foothold in the phenobarbital market, and it allowed the company to expand its product offerings.
  • In 2023, Mallinckrodt, Inc. entered into a partnership with Hikma Pharmaceuticals, a global pharmaceutical company. The partnership allows Mallinckrodt to market and distribute Hikma's phenobarbital products in the United States. This partnership gives Mallinckrodt a wider reach in the phenobarbital market, and it allows the company to expand its product offerings.
  • In 2023, Teva Pharmaceutical Industries, a global pharmaceutical company, acquired the assets of Mylan NV, a company that specialized in the development and commercialization of generic pharmaceuticals. This acquisition gave Teva Pharmaceutical a strong foothold in the generic phenobarbital market, and it allowed the company to expand its product offerings.

Figure 2. Global Phenobarbital Market Share (%), by Type, 2023

 | Coherent Market Insights

Top companies in Phenobarbital Market

  1. Sanofi
  2. Pfizer Inc.
  3. Novartis AG
  4. Teva Pharmaceutical Industries Ltd.
  5. Mylan N.V.
  6. Sun Pharmaceutical Industries Ltd.
  7. Hikma Pharmaceuticals
  8. Zydus Cadila
  9. Lannett Company, Inc.
  10. Strides Pharma Science Limited
  11. Cipla Ltd.
  12. Lupin Limited
  13. Aurobindo Pharma Limited
  14. Torrent Pharmaceuticals Ltd.
  15. Reddy's Laboratories Ltd.

*Definition: Phenobarbital is a medication belonging to the class of barbiturates. It is primarily used as an antiepileptic drug to control and prevent seizures in various forms of epilepsy. Phenobarbital works by slowing down the activity in the brain and nervous system, thereby reducing the occurrence of seizures. It is also sometimes used as a sedative or for the treatment of withdrawal symptoms associated with alcohol or drug dependence.

Frequently Asked Questions

The key factors hampering the growth of the Phenobarbital market include the availability of alternative antiepileptic drugs, concerns about tolerance and dependence, and potential adverse effects and safety concerns.

The major factors driving the Phenobarbital market growth include its established efficacy in treating epilepsy, its affordability and accessibility, the prevalence of epilepsy, and limited access to newer antiepileptic drugs in certain regions.

The leading component segment in the Phenobarbital market is the tablets segment.

The major players operating in the Phenobarbital market include Sanofi, Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals, Zydus Cadila, Lannett Company, Inc., Strides Pharma Science Limited, Cipla Ltd., Lupin Limited, Aurobindo Pharma Limited, Torrent Pharmaceuticals Ltd., and Dr. Reddy's Laboratories Ltd.

North America is expected to lead the Phenobarbital market, followed by Europe and the Asia Pacific region.
  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
  • Want to Buy a Report but have a Limited Budget?

    We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

    Request Discount

Reliability and Reputation

DUNS Registered
DMCA Protected


Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo